Pharmaceutical companies have historically been top-line focused. Due to a combination of patent law and block-buster drugs, they’ve been in a very strong position from a revenue standpoint (think Claratin, the little purple pill and the little blue pill). The model worked well for quite some time due to high volume, exclusivity and high prices [more]

[Read more →]

SpendMatters blogger and all around industry guru Jason Busch is back with another round of Category Chatter podcasts. In case you’re not familiar with the series, the podcasts feature Jason interviewing various Ariba Category Managers on hot topics of the day. If the area of spend they’re covering is of interest to you, Jason’s probing [more]

[Read more →]

Jason Busch of SpendMatters recently hosted a number of podcasts with our Category and Commodity Managers (many of whom will be familiar names to regular Supply Excellence readers). The Category Chatter podcast series dives deep, sometimes very deep into the market trends, pitfalls and opportunities in each of these areas:

Low-Cost Country Sourcing - Jason and [more]

[Read more →]